<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Warfarin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Warfarin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Warfarin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11147" href="/d/html/11147.html" rel="external">see "Warfarin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12886" href="/d/html/12886.html" rel="external">see "Warfarin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708848"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Warfarin can cause major or fatal bleeding. Perform regular monitoring of international normalized ratio (INR) on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin therapy. Instruct patients about prevention measures to minimize the risk of bleeding and to report immediately to their health care provider signs and symptoms of bleeding.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F234876"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Coumadin [DSC];</li>
<li>Jantoven</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868618"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Warfarin;</li>
<li>Coumadin [DSC];</li>
<li>TARO-Warfarin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F234916"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Vitamin K Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F234880"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The adult dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editor: Edith A Nutescu, PharmD, MS, FCCP.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Dosing must be individualized and use of an institutional protocol is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315259','lexi-content-ref-23585642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315259','lexi-content-ref-23585642'])">Ref</a></span>). Response to warfarin is influenced by numerous factors (eg, age, organ function) as described below. Genetic variations in metabolism (eg, CYP2C9 and/or VKORC1 genes) can impact warfarin sensitivity; however, routine genetic testing is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315259','lexi-content-ref-28198005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315259','lexi-content-ref-28198005'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3346169-5f71-401b-a694-0358919ef669">Anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anticoagulation: Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Initial:</i> 5 mg once daily for most patients. A lower or higher starting dose may be used depending upon patient-specific factors (see example warfarin initiation nomogram below). Although an elevation in INR can be seen as soon as 24 to 48 hours after the first dose due to depletion of factor VII, this does not represent therapeutic anticoagulation because other vitamin K–dependent clotting factors with longer half-lives (eg, factors II, IX, and X) must also be depleted. Accordingly, in patients at high risk for thromboembolism, overlap ("bridging") with a parenteral anticoagulant may be necessary during initiation of warfarin until a stable therapeutic INR is attained (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wittkowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wittkowsky.1'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Example Warfarin Initiation Nomogram Targeting an INR Range of 2 to 3 (for Outpatients or Clinically Stable Inpatients) (Adapted From Wittkowsky 2018)<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center"></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Standard dosing for patients who are <i>not</i> expected to be sensitive to warfarin<sup>b</sup></p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Reduced dosing for patients expected to be more sensitive to warfarin<sup>c</sup></b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>a</sup>Dosing nomograms offer a reasonable starting point for estimating an initial warfarin dose and subsequent adjustments but should not serve as a substitute for clinical judgment. If the patient received warfarin previously, history of prior dose requirement is useful for guiding reinitiation of therapy.</div>
</td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>b</sup>Patients who are generally started using “standard dosing” include otherwise healthy adults who are not receiving interacting medications.</div>
</td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>c</sup>Patients expected to be more sensitive to warfarin include adults who are frail, elderly, or undernourished; have liver disease, kidney disease, heart failure, or acute illness; or are receiving a medication known to decrease warfarin metabolism.</div>
</td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>d </sup>Young, healthy patients may start at 7.5 or 10 mg for the first 2 days (ACCP [Holbrook 2012]). A higher initial dose may also be appropriate in a patient who was previously treated with warfarin and required high doses or is receiving a medication that increases warfarin metabolism. However, this nomogram has not been validated for starting doses &gt;5 mg/day.</div>
</td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Initial dose</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 mg daily for 3 days<sup>d</sup></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.5 mg daily for 3 days</p></td></tr>
<tr>
<td align="center" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">Check INR the morning of day 4</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&lt;1.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">7.5 to 10 mg daily for 2 to 3 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 to 7.5 mg daily for 2 to 3 days</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.5 to 1.9</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">5 mg daily for 2 to 3 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.5 mg daily for 2 to 3 days</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.5 mg daily for 2 to 3 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.25 mg daily for 2 to 3 days</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">3.1 to 4</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.25 mg daily for 2 to 3 days</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">0.5 mg daily for 2 to 3 days</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">&gt;4</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Hold until INR &lt;3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Hold until INR &lt;3</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Maintenance:</i> Usual maintenance dose: 2 to 10 mg once daily. Once INR is therapeutic and stable following initiation, subsequent dosage requirements may be guided with the use of a maintenance dosing nomogram (see example warfarin maintenance dosing nomogram below). INR should be checked at least weekly when it is out of range and approximately every 4 weeks once therapeutic and stable. In chronic therapy, INR values are most affected by the doses administered 2 to 3 days prior to INR measurement.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Example Warfarin Maintenance Dosing Nomogram<sup>a</sup> (Adapted From Hadlock 2018)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Regular-intensity anticoagulation:</b>
<b>INR goal 2 to 3</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>High-intensity anticoagulation:</b>
<b>INR goal 2.5 to 3.5</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Suggested adjustment(s) to warfarin dose</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>a</sup>As with initiation therapy nomograms, maintenance therapy nomograms must be used in conjunction with clinical judgment.</div>
</td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<div class="reference">
<sup>b</sup>As an example, a patient with an INR goal of 2 to 3 and receiving 30 mg of warfarin per week (eg, administered as 5 mg on 5 days and 2.5 mg on 2 days) has an INR result of 1.4. The weekly dose should be increased by 10% to 20% (eg, increase to 35 mg per week by administering 5 mg once daily). A one-time supplemental dose of 7.5 mg may be considered on the day INR was checked, then start new maintenance dose (eg, 5 mg daily) the following day.</div>
</td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Adjustment(s) for subtherapeutic (low) INR – Note:</b> If the factor causing subtherapeutic INR is transient (eg, missed warfarin dose or temporary change in vitamin K intake), consider resumption of prior maintenance dose following a one-time supplemental dose, if indicated.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR &lt;1.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR &lt;2</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Increase weekly maintenance dose by 10% to 20%<sup>b</sup></p>
<p style="text-indent:0em;margin-top:2em;">• Consider a one-time supplemental dose of 1.5 to 2 times the daily maintenance dose<sup>b</sup></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 1.5 to 1.7</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 2 to 2.2</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Increase weekly maintenance dose by 5% to 15%</p>
<p style="text-indent:0em;margin-top:2em;">• Consider a one-time supplemental dose of 1.5 to 2 times the daily maintenance dose</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 1.8 to 1.9</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 2.3 to 2.4</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• No dosage adjustment may be necessary if the last 2 INRs were in range, if there is no clear explanation for the INR to be out of range, and, if in the judgment of the clinician, the INR does not represent an increased risk of thromboembolism for the patient; additional monitoring may be warranted</p>
<p style="text-indent:0em;margin-top:2em;">• If dosage adjustment needed, increase weekly maintenance dose by 5% to 10%</p>
<p style="text-indent:0em;margin-top:2em;">• Consider a one-time supplemental dose of 1.5 to 2 times the daily maintenance dose</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>INR within therapeutic range </b></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 2.5 to 3.5</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">Desired range; no adjustment needed</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Adjustment(s) for supratherapeutic (high) INR – Note:</b> If the factor causing elevated INR is transient (eg, temporary change in vitamin K intake, acute illness, acute alcohol ingestion), consider resumption of prior maintenance dose following dose(s) held and low-dose oral vitamin K, if indicated.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 3.1 to 3.2</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 3.6 to 3.7</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• No dosage adjustment may be necessary if the last 2 INRs were in range, if there is no clear explanation for the INR to be out of range, and, if in the judgment of the clinician, the INR does not represent an increased risk of hemorrhage to patient; additional monitoring may be warranted</p>
<p style="text-indent:0em;margin-top:2em;">• If dosage adjustment needed, decrease weekly maintenance dose by 5% to 10%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 3.3 to 3.4</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 3.8 to 3.9</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Decrease weekly maintenance dose by 5% to 10%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 3.5 to 3.9</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR 4 to 4.4</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Consider holding 1 dose</p>
<p style="text-indent:0em;margin-top:2em;">• Decrease weekly maintenance dose by 5% to 15%</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR <span style="text-decoration: underline">&gt;</span>4 but ≤10 and no bleeding</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR <span style="text-decoration: underline">&gt;</span>4.5 but ≤10 and no bleeding</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Hold until INR below upper limit of therapeutic range</p>
<p style="text-indent:0em;margin-top:2em;">• Decrease weekly maintenance dose by 5% to 20%</p>
<p style="text-indent:0em;margin-top:2em;">• If patient considered to be at significant risk for bleeding, consider low-dose oral vitamin K</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;text-align:center;">INR &gt;10 and no bleeding</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">INR &gt;10 and no bleeding</p></td>
<td align="left" valign="middle">
<p style="text-indent:0em;">• Hold until INR below upper limit of therapeutic range</p>
<p style="text-indent:0em;margin-top:2em;">• Administer vitamin K orally</p>
<p style="text-indent:0em;margin-top:2em;">• Decrease weekly maintenance dose by 5% to 20%</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Warfarin: Adult Target INR Ranges Based Upon Indication</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Indication</b></p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Targeted INR range</b></p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">
<b>Treatment duration</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">LV = left ventricular; MI = myocardial infarction.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Cardiac</b></p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Atrial fibrillation or atrial flutter</b></i> (AHA/ACC/HRS [January 2014, January 2019]).</p>
<p style="text-indent:0em;">
<b>Note: </b>For eligible patients with <i>nonvalvular </i>atrial fibrillation, a direct oral anticoagulant is recommended over warfarin (AHA/ACC/HRS [January 2014, January 2019]).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>
<i>LV thrombus, treatment post MI</i>
<sup></sup></b>(ACCF/AHA [O’Gara 2013]; ACCP [Vandvik 2012]; AHA [Levine 2022]).</p>
<p style="text-indent:0em;">
<b>Note:</b> When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for MI may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (ACC [Kumbhani 2021]; AHA [Levine 2022]).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">≥3 to 6 months after MI.</p>
<p style="text-indent:0em;">
<b>Note:</b> For acute MI, ~3 months is reasonable. For more distant MI, 3 to 6 months is reasonable. Duration may vary based on follow-up imaging (eg, assessment of thrombus resolution, LV function) and shared decision making; indefinite therapy may be considered if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>
<i>LV thrombus, prophylaxis for high-risk patients post MI</i></b> (eg, ejection fraction &lt;40% and/or anteroapical wall motion abnormality) (ACCF/AHA [O’Gara 2013]; ACCP [Vandvik 2012]; AHA [Levine 2022]).</p>
<p style="text-indent:0em;">
<b>Note:</b> When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for MI may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (ACC [Kumbhani 2021]; AHA [Levine 2022]).</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 3 months after MI.</p>
<p style="text-indent:0em;">
<b>Note:</b> Duration may vary based on follow-up imaging (eg, assessment of LV function) and shared decision making.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>
<i>LV thrombus treatment in patients with nonischemic dilated cardiomyopathy </i></b>(ACCP [Vandvik 2012]; AHA [Levine 2022])</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center">
<p style="text-indent:0em;">≥3 to 6 months.</p>
<p style="text-indent:0em;">
<b>Note:</b> Duration may vary based on follow-up imaging (eg, assessment of thrombus resolution and LV function) and shared decision making; indefinite therapy may be considered even after thrombus resolution if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Valvular</b>
<b> – Note:</b> For mechanical valves, combination therapy with aspirin is not routinely required, except for patients who receive an On-X mechanical aortic valve. For surgically placed bioprosthetic valves in patients at low risk of bleeding, warfarin is suggested for the first 3 to 6 months after surgery followed by aspirin monotherapy; for patients at elevated risk of bleeding, initiating aspirin monotherapy after surgery and continuing long term may be appropriate (ie, no initial use of warfarin after surgery). When choosing antithrombotic therapy, additional risk factors for thromboembolism (eg, atrial fibrillation, previous thromboembolism, left ventricular systolic dysfunction, hypercoagulable conditions) should be considered. The goal INR is generally the central value in the indicated acceptable range, especially for patients with a mechanical valve (ACC/AHA [Otto 2021]; Puskas 2014).</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>On-X mechanical bileaflet aortic valve without additional risk factors for thromboembolism</b></i> (ACC/AHA [Otto 2021]; Puskas 2014)</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Months 1 to 3:</p>
<p style="text-indent:0em;">2 to 3</p>
<p style="text-indent:0em;">Month 4 and after:</p>
<p style="text-indent:0em;">1.5 to 2</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Mechanical bileaflet aortic valve (other than On-X) without additional risk factors for thromboembolism </b></i></p>
<p style="text-indent:0em;">
<i>
<b>or </b></i></p>
<p style="text-indent:0em;">
<b>
<i>Current-generation single-tilting disc aortic valve without additional risk factors for thromboembolism</i></b></p>
<p style="text-indent:0em;">
<i>
<b>or</b></i></p>
<p style="text-indent:0em;">
<b>
<i>On-X mechanical bileaflet aortic valve with additional risk factors for thromboembolism </i></b>(ACC/AHA [Otto 2021]; Puskas 2014)</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Current-generation mechanical aortic valve with additional risk factors for thromboembolism </b></i></p>
<p style="text-indent:0em;">
<i>
<b>or </b></i></p>
<p style="text-indent:0em;">
<b>
<i>Older-generation mechanical aortic valve (eg, ball-in-cage) without additional risk factors for thromboembolism</i></b></p>
<p style="text-indent:0em;">
<i>
<b>or</b></i></p>
<p style="text-indent:0em;">
<i>
<b>Current-generation mechanical mitral valve with or without additional risk factors for thromboembolism</b></i> (ACC/AHA [Otto 2021])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2.5 to 3.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>
<i>Older-generation mechanical aortic valve (eg, ball-in-cage) with additional risk factors for thromboembolism</i></b></p>
<p style="text-indent:0em;">
<b>
<i>or </i></b></p>
<p style="text-indent:0em;">
<i>
<b>Older-generation mechanical mitral valve (eg, ball-in-cage) with or without additional risk factors for thromboembolism</b></i> (Konkle 2022)</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 4</p></td>
<td align="center">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Surgically placed bioprosthetic aortic or mitral valve at low risk of bleeding</b></i> (ACC/AHA [Otto 2021])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">3 to 6 months</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Rheumatic mitral stenosis with atrial fibrillation, previous systemic embolism, or left atrial thrombus</b></i> (ACC/AHA [Otto 2021])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>
<i>Thrombosis of bioprosthetic valve, nonurgent management</i></b></p>
<p style="text-indent:0em;text-align:left;">
<b>Note:</b> Some experts limit use to left-sided (aortic or mitral) bioprosthetic valve thrombosis and favor fibrinolysis for right-sided bioprosthetic valve thrombosis (Pislaru 2022). Target INR and duration of therapy may vary depending on antithrombotic regimen at the time of thrombosis. Regularly assess (ie, every 30 days) for improvement in signs and symptoms (AHA/ACC [Otto 2021]; Butnaru 2013; Chakravarty 2017; Jose 2017; Latib 2015; Makkar 2015; Pislaru 2015; Pislaru 2022).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">≥6 months after thrombus resolution</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<b>Acute venous thromboembolism treatment – Note:</b> For eligible patients, a direct oral anticoagulant is recommended over warfarin. When warfarin is selected for long-term treatment, a parenteral anticoagulant must be used initially as a bridge until INR measurements are therapeutic and stable. Start warfarin on the first or second day of parenteral anticoagulation and overlap until INR is ≥2 for at least 2 days. Duration of overlap is ~5 days (ACCP [Ageno 2012]). The optimal duration of warfarin therapy is dependent on several factors, such as presence of provoking events, patient risk factors for recurrence or bleeding, and patient preferences. If indefinite treatment is suggested, reassess need for anticoagulation at periodic intervals (ACCP [Stevens 2021]).</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Venous thromboembolism, provoked </b></i>(ACCP [Stevens 2021])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Minimum of 3 months</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Venous thromboembolism, unprovoked</b></i> (ACCP [Stevens 2021]; ISTH [Baglin 2012])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Minimum of 3 months and up to indefinite</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<b>Thromboprophylaxis</b></p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Idiopathic or inherited pulmonary artery hypertension</b></i> (ACCF/AHA [McLaughlin 2009]; ACCP [Klinger 2019]; ESC/ERS [Humbert 2022]; Olsson 2014)</p>
<p style="text-indent:0em;">
<b>Note:</b> Anticoagulation should be considered on an individual basis for patients with idiopathic or inherited pulmonary arterial hypertension after considering risks and benefits. Avoid anticoagulation in patients with scleroderma-associated pulmonary arterial hypertension (ESC/ERS [Humbert 2022]; Khan 2018; Olsson 2014).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">1.5 to 2.5</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Chronic thromboembolic pulmonary arterial hypertension</b></i> (ACCF/AHA [McLaughlin 2009]; ESC/ERS [Humbert 2022])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Antiphospholipid syndrome</b></i> (ACCP [Holbrook 2012]; Erkan 2019)</p>
<p style="text-indent:0em;">
<b>Note:</b> Antiphospholipid syndrome is an autoimmune syndrome characterized by venous or arterial thrombosis and/or pregnancy loss in the presence of persistent antiphospholipid antibodies. Patients with antiphospholipid antibodies alone, without a history of thromboembolism, should <b>not </b>receive anticoagulation unless another indication exists. The PT/INR may be prolonged at baseline, in the absence of anticoagulation, in a small percentage of patients due to the presence of antiphospholipid antibodies. This should <b>not</b> be considered a therapeutic effect. An alternative method for monitoring warfarin may be necessary (Erkan 2019).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Indefinite</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Total hip arthroplasty or hip fracture surgery </b></i></p>
<p style="text-indent:0em;">
<b>Note:</b> May be used as an alternative to low-molecular-weight heparin or low-dose SubQ heparin (ACCP [Falck-Ytter 2012]).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Minimum of 10 to 14 days and up to 35 days</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">
<i>
<b>Total knee arthroplasty</b></i></p>
<p style="text-indent:0em;">
<b>Note:</b> May be used as an alternative to low-molecular-weight heparin or low-dose SubQ heparin (ACCP [Falck-Ytter 2012]).</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Typically, 10 to 14 days, but consider up to 35 days if there are multiple or persistent risk factors</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<b>Heparin-induced thrombocytopenia – Note:</b> If a patient is taking warfarin at the time of diagnosis, it should be discontinued, and vitamin K should be administered to reverse its effect. Initial therapy should be with a parenteral nonheparin anticoagulant. Warfarin may be initiated after the patient has been stably anticoagulated with a parenteral nonheparin anticoagulant and the platelet count has recovered (eg, ≥150 × 10<sup>9</sup>/L or at the patient's baseline). Starting dose should be ≤5 mg once daily. Overlap the parenteral nonheparin anticoagulant with warfarin for ≥5 days and until INR is therapeutic. Some nonheparin anticoagulants may elevate INR, complicating interpretation. Recheck INR after effects of the nonheparin anticoagulant have worn off to ensure INR remains therapeutic (ACCP [Linkins 2012]; ASH [Cuker 2018]).</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;text-align:left;">Heparin-induced thrombocytopenia <b>without </b>thrombosis (ACCP [Linkins 2012]; ASH [Cuker 2018])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">4 weeks to 3 months (ACCP [Linkins 2012]). Alternatively, may discontinue anticoagulation after platelet count recovery, potentially resulting in a shorter duration (ASH [Cuker 2018]).</p></td></tr>
<tr>
<td align="left" valign="middle">
<p style="text-indent:0em;">Heparin-induced thrombocytopenia <b>with </b>thrombosis (ACCP [Linkins 2012]; ASH [Cuker 2018])</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">2 to 3</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Optimal duration not well established. Typically, 3 to 6 months (ACCP [Linkins 2012]; ASH [Cuker 2018]).</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between anticoagulants:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning from another anticoagulant to warfarin: Note:</b> Apixaban, dabigatran, edoxaban, and rivaroxaban can elevate INR, complicating interpretation if overlapped with warfarin. To minimize interference, check INR near end of direct oral anticoagulant dosing interval.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from apixaban to warfarin: </i></b>Some experts suggest overlapping apixaban with warfarin for ≥2 days until INR is therapeutic. An alternative is to stop apixaban, start warfarin the same day, and bridge with a parenteral anticoagulant until the desired INR is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from dabigatran to warfarin: </i></b>One option is to stop dabigatran, start warfarin the same day, and bridge with a parenteral anticoagulant until the desired INR is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>). An alternative option is to overlap the 2 agents. If this is done, the timing of warfarin initiation is based on CrCl as outlined below:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &gt;50 mL/minute: Initiate warfarin 3 days before discontinuing dabigatran.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 50 mL/minute: Initiate warfarin 2 days before discontinuing dabigatran.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 15 to 30 mL/minute: Initiate warfarin 1 day before discontinuing dabigatran.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;15 mL/minute: Dosing recommendations cannot be provided. Dabigatran is not recommended for use in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from edoxaban to warfarin:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral option:</i> For patients taking edoxaban 60 mg once daily, reduce the dose to 30 mg once daily and begin warfarin concomitantly. For patients taking edoxaban 30 mg once daily, reduce the dose to 15 mg once daily and begin warfarin concomitantly. Discontinue edoxaban once a stable INR ≥2 is achieved; continue warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Parenteral option:</i> Discontinue edoxaban and initiate a parenteral anticoagulant and warfarin at the time of the next scheduled edoxaban dose. Discontinue the parenteral anticoagulant once a stable INR ≥2 is achieved; continue warfarin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from rivaroxaban to warfarin:</i></b> Some experts suggest overlapping rivaroxaban with warfarin for ≥2 days until INR is therapeutic. An alternative is to stop rivaroxaban, start warfarin the same day, and bridge with a parenteral anticoagulant until the desired INR is reached (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from therapeutic-dose parenteral anticoagulant to warfarin: </i></b>Start warfarin and continue parenteral anticoagulant until INR is within therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-Wittkowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-Wittkowsky.1'])">Ref</a></span>). <b>Note:</b> Overlap parenteral anticoagulant with warfarin until INR is ≥2 for at least 2 days (duration of overlap is ~5 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315269','lexi-content-ref-Hull.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315269','lexi-content-ref-Hull.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transitioning from warfarin to another anticoagulant: </b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In general, it is reasonable to discontinue warfarin and initiate another anticoagulant as soon as INR is ≤2 depending on the indication and risks of thrombosis and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1'])">Ref</a></span>). Specific recommendations from manufacturers include:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from warfarin to apixaban: </i></b>Discontinue warfarin and initiate apixaban as soon as INR falls to &lt;2 (US labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from warfarin to dabigatran: </i></b>Discontinue warfarin and initiate dabigatran as soon as INR falls to &lt;2 (US labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from warfarin to edoxaban</i></b>: Discontinue warfarin and initiate edoxaban as soon as INR falls to ≤2.5 (US labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from warfarin to rivaroxaban:</i></b> Discontinue warfarin and initiate rivaroxaban as soon as INR falls to &lt;3 (US labeling) or ≤ 2.5 (Canadian labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from warfarin to parenteral anticoagulation: </i></b>Stop warfarin and start the parenteral anticoagulant when INR is as close as possible to the lower end of the targeted INR range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wittkowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wittkowsky.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990712"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> There are no specific dosage adjustments recommended for any degree of kidney impairment. However, compared to patients with normal kidney function, retrospective data suggest patients with eGFR &lt;60 mL/minute/1.73 m<sup>2 </sup>tend to require ~10% to 20% lower warfarin doses and are at higher risk of overanticoagulation and bleeding. Consider starting with lower initial doses in these patients and more frequent INR monitoring, especially if the patient has additional risk factors for warfarin sensitivity (eg, elderly, eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19225037','lexi-content-ref-20709439','lexi-content-ref-24851819','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19225037','lexi-content-ref-20709439','lexi-content-ref-24851819','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): Patients with end-stage kidney disease (ESKD) tend to require ~20% lower doses compared to patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24851819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24851819'])">Ref</a></span>) and have a significant risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720522'])">Ref</a></span>). Use lower initial doses and monitor INR frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19225037','lexi-content-ref-24851819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19225037','lexi-content-ref-24851819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): Patients with ESKD tend to require ~20% lower doses compared to patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24851819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24851819'])">Ref</a></span>) and have a significant risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17720522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17720522'])">Ref</a></span>). Use lower initial doses and monitor INR frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19225037','lexi-content-ref-24851819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19225037','lexi-content-ref-24851819'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988058"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, the response to oral anticoagulants may be markedly enhanced in obstructive jaundice, hepatitis, and cirrhosis. INR should be closely monitored.</p></div>
<div class="block doe drugH1Div" id="F234881"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Patients &gt;60 years of age tend to require lower dosages to produce a therapeutic level of anticoagulation (due to changes in the pattern of warfarin metabolism). Avoid as initial treatment of venous thromboembolism or nonvalvular atrial fibrillation (unless contraindications or substantial barriers to alternative options). In older adults already on long-term therapy, continued therapy may be reasonable, especially if INRs are well controlled and there are no adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F234898"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12886" href="/d/html/12886.html" rel="external">see "Warfarin: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Labeling identifies genetic factors which may increase patient sensitivity to warfarin based on experience in adult patients. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin's primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. Genotyping tests are available and may provide guidance on initiation of anticoagulant therapy. Routine genetic testing is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315259','lexi-content-ref-28198005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315259','lexi-content-ref-28198005'])">Ref</a></span>). For management of elevated INRs as a result of warfarin therapy, see Phytonadione monograph or ACCP Guidelines for additional information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e64a3aa5-657e-4910-a295-bbcf22e0d879">Thromboembolic complications; prophylaxis and treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboembolic complications; prophylaxis and treatment: </b>Limited data available: Individualize dose to achieve target INR based on indication; INRs are primarily extrapolated from adult experience; although there may be some exceptions, for most indications the therapeutic target INR is 2.5 (range: 2 to 3), and for low-dose prophylaxis, a target INR is 1.7 (range: 1.5 to 1.9) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>); see "Reference Range" for more information and consult expert guidelines.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Target INR between 2 to 3 (eg, treatment)</i>
<i>: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Initial loading dose (if baseline INR is 1 to 1.3): Oral: 0.2 mg/kg/day once daily; maximum dose: 10 mg/dose; use a reduced initial loading dose of 0.1 mg/kg if patient has undergone a Fontan procedure or has liver dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-24226806','lexi-content-ref-10556183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-24226806','lexi-content-ref-10556183'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Days 2 to 4: Additional loading doses are dependent upon patient's INR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>): Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">INR 1.1 to 1.3: Repeat the initial loading dose.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 1.4 to 1.9: Dose is 50% of the initial loading dose.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 2 to 3: Dose is 50% of the initial loading dose.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 3.1 to 3.5: Dose is 25% of the initial loading dose.</p>
<p style="text-indent:-2em;margin-left:10em;">INR &gt;3.5: Hold the drug until INR &lt;3.5, then restart at 50% of previous dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Days ≥5: Maintenance doses are dependent upon patient's INR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>): Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">INR 1.1 to 1.4: Increase previous dose by 20%.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 1.5 to 1.9: Increase previous dose by 10%.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 2 to 3: No change in dose.</p>
<p style="text-indent:-2em;margin-left:10em;">INR 3.1 to 3.5: Decrease previous dose by 10%.</p>
<p style="text-indent:-2em;margin-left:10em;">INR &gt;3.5: Hold the drug until INR &lt;3.5, then restart at 20% less than the previous dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193562"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No adjustment required; however, patients with renal failure have an increased risk of bleeding complications. Monitor closely.</p></div>
<div class="block dohp drugH1Div" id="F51193563"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, the response to oral anticoagulants may be markedly enhanced in obstructive jaundice (due to reduced vitamin K absorption) and also in hepatitis and cirrhosis (due to decreased production of vitamin K-dependent clotting factors); INR should be closely monitored.</p></div>
<div class="block arsc drugH1Div" id="F57207745"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Atheroemboli/cholesterol microemboli</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atheromatous embolism/cholesterol embolus syndrome</b> have rarely been reported with warfarin use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9619702','lexi-content-ref-26381781','lexi-content-ref-3605140','lexi-content-ref-20308269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9619702','lexi-content-ref-26381781','lexi-content-ref-3605140','lexi-content-ref-20308269'])">Ref</a></span>). Symptoms depend on the site of embolization, with the most common sites as the kidneys, pancreas, liver, and spleen. In some cases, atheroemboli/cholesterol microemboli may be fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-Pasupala.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-Pasupala.2012'])">Ref</a></span>). Cholesterol microembolization may lead to “<b>purple toe</b>” <b>syndrome</b>, which presents as a dark, purplish, mottled discoloration of the plantar and lateral surfaces (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3605140','lexi-content-ref-20308269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3605140','lexi-content-ref-20308269'])">Ref</a></span>). Other manifestations of cholesterol microembolization may include <b>skin rash</b>; <b>livedo reticularis</b>; <b>gangrene of skin and/or subcutaneous tissues</b>; abrupt and intense <b>lower extremity pain</b>; <b>abdominal pain</b>, flank pain, or back pain; <b>hematuria</b>; hypertension; cerebral ischemia; spinal cord infarction; or other symptoms of vascular compromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24925541','lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-20308269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24925541','lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-20308269'])">Ref</a></span>). Symptoms are typically reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31439554','lexi-content-ref-20308269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31439554','lexi-content-ref-20308269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; anticoagulation with warfarin may induce plaque hemorrhage, subsequently causing the release of cholesterol crystals and particles within the atheromatous plaques, resulting in microemboli, vessel occlusion, and inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25197328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25197328'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; cases have been reported from after 2 weeks to 6 months of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24925541','lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-20308269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24925541','lexi-content-ref-3605140','lexi-content-ref-31439554','lexi-content-ref-20308269'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Protein C deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24925541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24925541'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Atherosclerotic disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12875753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12875753'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12875753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12875753'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12875753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12875753'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevations in baseline C-reactive protein (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12875753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12875753'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28469497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28469497'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Calciphylaxis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and fatal <b>calciphylaxis</b> (calcium uremic arteriolopathy) has rarely been reported in association with warfarin use in patients with and without end-stage kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26783010','lexi-content-ref-32528755','lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26783010','lexi-content-ref-32528755','lexi-content-ref-28099971'])">Ref</a></span>). Signs and symptoms may include stellate ulcers with purpuric borders, fixed livedo, retiform purpura, ischemia/necrosis, blistering/ulceration, abdominal pain, and thrombosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33391959','lexi-content-ref-26783010','lexi-content-ref-32528755','lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33391959','lexi-content-ref-26783010','lexi-content-ref-32528755','lexi-content-ref-28099971'])">Ref</a></span>). Symptoms typically resolve upon discontinuation and may require additional treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33391959','lexi-content-ref-23581997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33391959','lexi-content-ref-23581997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action; inhibits vitamin K–dependent matrix Gla protein, which is responsible for preventing calcium deposition in vessels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099971'])">Ref</a></span>). Warfarin paradoxically incites thrombosis and inhibits normal endothelial cell responses to calcification by decreasing proteins C and S synthesis in endothelial cells, which regulate procoagulant and anticoagulant factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099971'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; duration of warfarin prior to calciphylaxis ranged from 1 month to 14 years with an average of ~2.6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099971'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099971'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Peripheral vascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099971'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperphosphatemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23966800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23966800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypercalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23966800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23966800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperparathyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23966800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23966800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low serum albumin levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23966800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23966800'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23966800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23966800'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Decreased bone mineral density</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Decreased bone mineral density</b> (BMD) has been reported in children and adolescents receiving long-term warfarin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-15695604','lexi-content-ref-25511666','lexi-content-ref-28552474','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-15695604','lexi-content-ref-25511666','lexi-content-ref-28552474','lexi-content-ref-31652944'])">Ref</a></span>); available data in adult patients are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31652944'])">Ref</a></span>). A significant reduction in lumbar spinal bone mineral apparent density (BMAD) scores was reported in a case control study (age range: 8 to 18 years; mean duration of warfarin treatment was 8.2 years [range: 1 to 14 years]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15695604','lexi-content-ref-28552474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15695604','lexi-content-ref-28552474'])">Ref</a></span>). Another cohort study (age range: 5 to 12 years) reported significant reductions of spinal BMD z-score and lower total body less head BMD z-score (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25511666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25511666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to mechanism of action; modulates carboxylation range of glutamic acid residues in osteocalcin. Carboxylated osteocalcin weakly binds to and accumulates in the bone matrix (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31652944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; associated with prolonged duration of treatment. Although an exact duration has not been defined, a duration of &gt;1 year has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-31652944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged duration of treatment; exact duration not defined but &gt;1 year has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-31652944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-31652944'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemorrhage</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Warfarin can cause <b>major </b>(or fatal) <b>hemorrhage </b>in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-23184840']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-23184840'])">Ref</a></span>). Given the prevalence and seriousness of this reaction, the US product labeling includes a boxed warning regarding the risk of major and fatal bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>). Upon discontinuation, warfarin-induced bleeding is reversible; however, reversal may be delayed without reversal agents due to the long half-life.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; related to the pharmacologic action. Warfarin inhibits vitamin K epoxide reductase subunit 1, depleting functional vitamin K from activating clotting factors II, VII, IX, and X and proteins C and S (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16369639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16369639'])">Ref</a></span>). Of note, decreased plasma levels of vitamin K–dependent coagulation factors in neonates and a continuously changing hemostatic system in infants has been well described and associated with an increased risk of bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-22187399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-22187399'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bleeding may occur at any time. However, bleeding risk is highest within the first 30 days of therapy in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23184840','lexi-content-ref-30701002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23184840','lexi-content-ref-30701002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Use of loading doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16369639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16369639'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long duration of therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Highly variable INRs</p>
<p style="text-indent:-2em;margin-left:6em;">• Elevated INR (&gt;3, especially &gt;4) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30701002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30701002'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients, especially neonates, infants, and children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Adult patients ≥65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15509671','lexi-content-ref-30701002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15509671','lexi-content-ref-30701002'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that increase bleeding risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222786'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15509671','lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15509671','lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15509671','lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15509671','lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cerebrovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15509671','lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15509671','lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17620536']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17620536'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric specific issues:</p>
<p style="text-indent:-2em;margin-left:8em;">- Breastfed neonates and infants (low concentrations of vitamin K in breast milk) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Rapidly changing physiologic values of vitamin K–dependent coagulation proteins in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Frequent dietary changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Frequent changes in medication regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Lack of an oral liquid formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315277','lexi-content-ref-34872740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315277','lexi-content-ref-34872740'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Skin necrosis/gangrene</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Warfarin-induced<b> skin necrosis</b> is a very rare condition that may lead to surgery, debridement, or death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693','lexi-content-ref-19615543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693','lexi-content-ref-19615543'])">Ref</a></span>). Manifestations include painful purpuric lesions, skin mottling, arterial or venous thrombosis, hemorrhagic bullae, and overt cutaneous necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569516','lexi-content-ref-19615543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569516','lexi-content-ref-19615543'])">Ref</a></span>). Symptoms are reversible upon discontinuation of warfarin and treatment with vitamin K and fresh frozen plasma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; not clearly established; may be due to the paradoxical shift to a hypercoagulable state in the initial days of warfarin therapy secondary to inhibition of proteins C and S synthesis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs within the first five days of therapy but has been reported later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569516','lexi-content-ref-19615543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569516','lexi-content-ref-19615543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Large loading doses of warfarin, particularly in the presence of no concomitant heparinization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Protein C or S deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Factor V Leiden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperhomocysteinanemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antiphospholipid antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24648693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24648693'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F234840"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Dermatologic: Gangrene of skin and/or subcutaneous tissues, skin necrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous rash, dermatitis, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, bloating, diarrhea, dysgeusia, flatulence, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atheromatous embolism (Munawar 2019), cholesterol embolus syndrome (Hyman 1987), livedo reticularis (Cakebread 2014), purple toe syndrome (Varis 2010), vascular calcification (calcium uremic arteriolopathy and calciphylaxis) (Yu 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Watras 2016), skin rash (Cakebread 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (Munawar 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (including minor and major hemorrhage) (ACCP [Monagle 2012]; Gomes 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (Hepponstall 2017), lower extremity pain (Cakebread 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Munawar 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tracheobronchial calcification (Eckersley 2014; Golding 2013; Kansara 2019)</p></div>
<div class="block coi drugH1Div" id="F234856"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to warfarin or any component of the formulation; hemorrhagic tendencies (eg, active GI ulceration, patients bleeding from the GI, respiratory, or GU tract; cerebral aneurysm; CNS hemorrhage; dissecting aortic aneurysm; spinal puncture and other diagnostic or therapeutic procedures with potential for significant bleeding); recent or potential surgery of the eye or CNS; major regional lumbar block anesthesia or traumatic surgery resulting in large, open surfaces; blood dyscrasias; malignant hypertension; pericarditis or pericardial effusion; bacterial endocarditis; unsupervised patients with conditions associated with a high potential for noncompliance; eclampsia/preeclampsia, threatened abortion, pregnancy (except in women with mechanical heart valves at high risk for thromboembolism) </p></div>
<div class="block war drugH1Div" id="F234837"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: High risk for hemorrhage postsurgery: Avoid warfarin if possible immediately after gastric bypass and sleeve gastrectomy; significant risk for hemorrhage, readmission, and mortality (Bechtel 2013). Several studies have observed warfarin dose reduction postoperatively with a subsequent return to preoperative doses 6 to 12 months after surgery (Irwan 2013; Schullo-Feulner 2014; Steffen 2015; Strong 2018). The change in dose requirement may be multifactorial but is most likely due to attributable variation in the time to resuming full solid intake and the consequent alteration in the intake of vitamin K-containing foods. Monitor INR closely in the early postoperative period and up to 1 year after surgery or when significant nutritional or supplementation changes occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dietary insufficiency: Use with caution in patients with prolonged dietary insufficiencies (vitamin K deficiency).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and venous thromboembolism; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped. Warfarin monotherapy is contraindicated in the initial treatment of heparin-induced thrombocytopenia; warfarin initially inhibits the synthesis of protein C, potentially accelerating the underlying active thrombotic process.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Reduced liver function, regardless of etiology, may impair synthesis of coagulation factors leading to increased warfarin sensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Use with caution in patients with acute infection or active TB or any disruption of normal GI flora; antibiotics and fever may alter response to warfarin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Patients with renal impairment are at increased risk for bleeding diathesis; frequent INR monitoring is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with thyroid disease; warfarin responsiveness may increase (ACCP [Ageno 2012]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: The elderly may be more sensitive to anticoagulant therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with genomic variants in CYP2C9 and/or VKORC1: Presence of the CYP2C9*2 or *3 allele and/or polymorphism of the vitamin K oxidoreductase (VKORC1) gene may have increased sensitivity to warfarin (eg, lower doses needed to achieve therapeutic anticoagulation). The *2 allele is reported to occur with a frequency of 4% to 11% in African-Americans and Caucasians, respectively, while the *3 allele frequencies are 2% to 7% respectively. Other variant 2C9 alleles (eg, *5, *6, *9, and *11) are also associated with reduced warfarin metabolism and thus may increase sensitivity to warfarin, but are much less common. Lower doses may be required in these patients. Genetic testing may help determine appropriate dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: When temporary interruption is necessary before surgery, discontinue for ~5 days before surgery. When there is adequate hemostasis, may reinstitute warfarin within 24 hours after surgery at the patient’s usual maintenance dose. Decision to safely continue warfarin therapy through the procedure and whether or not bridging of anticoagulation is necessary is dependent upon risk of perioperative bleeding and risk of thromboembolism. If risk of thromboembolism is elevated, consider bridging warfarin therapy with an alternative anticoagulant (eg, unfractionated heparin or low-molecular-weight heparin) (ACCP [Douketis 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Patient selection: Use care in the selection of patients appropriate for this treatment; ensure patient cooperation especially from the alcoholic, illicit drug user, demented, or psychotic patient; ability to comply with routine laboratory monitoring is essential.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878672"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;">Vitamin K-antagonist (VKA) (eg, warfarin) therapy is usually avoided in neonates and infants &lt;4 months due to pharmacodynamic and administration issues which result in a greater risk of bleeding and necessitate more frequent monitoring and dose adjustment in these patients. Pharmacodynamic issues which create problematic dosing and monitoring include: Physiologically decreased neonatal plasma levels of vitamin K-dependent clotting factors (comparable to an adult with an INR 2 to 3 on VKA therapy), and a lower concentration of vitamin K in breast milk relative to infant formula (which is supplemented) making breast-fed infants very sensitive to VKA therapy (eg, much lower doses required to achieve target INR). Administration is problematic since no oral liquid formulation of warfarin is available; although some centers dissolve the appropriate tablet/dose in water, data which verifies stability and full assessment of practice is lacking (ACCP [Monagle 2012]; Hepponstall 2017).</p></div>
<div class="block foc drugH1Div" id="F234849"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 1 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 2 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 2.5 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 3 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 4 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 5 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 6 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 7.5 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 10 mg [DSC] [dye free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 1 mg [scored; contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 2 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 2.5 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 3 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 4 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 5 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 6 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 7.5 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jantoven: 10 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F234833"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F234858"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Jantoven Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $0.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $0.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.95</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Warfarin Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.29 - $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.29 - $0.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.29 - $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $0.29 - $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.29 - $0.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.29 - $0.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $0.36 - $0.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $0.36 - $0.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.36 - $1.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868619"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 1 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 2 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 2.5 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 3 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 4 mg [DSC] [contains fd&amp;c blue #1 (brill blue) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 5 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Coumadin: 6 mg [DSC], 10 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F234853"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food. Warfarin should be administered orally once a day at approximately the same time. In clinical practice, patients are often encouraged to take their dose later in the day to facilitate implementation of needed dose changes identified at daytime monitoring visits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wittkowsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wittkowsky.1'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614019"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food. Take at the same time each day.</p></div>
<div class="block hazard drugH1Div" id="F49104604"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F7874933"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F009218s017lbl.pdf%23page%3D31&amp;token=rDUguuTslPRpKDxOJx3c%2Fr8jpsWXElVervv6K6zPDgEtXs%2FdGflC%2FsqF9bcqKbQEZqN9jQCORCPQemPqv21V3FOaUuobOvY4hMWjuCavFi7Ef2ozGv1OIgCUqN8H9dsr&amp;TOPIC_ID=10050" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s017lbl.pdf#page=31</a> (Coumadin), must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F234852"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction:</b> Adjunct to reduce risk of systemic embolism (eg, recurrent myocardial infarction, stroke) after myocardial infarction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboembolic complications:</b> Prophylaxis and treatment of thromboembolic disorders (eg, venous, pulmonary) and embolic complications arising from atrial fibrillation or cardiac valve replacement.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Limitations of use: Warfarin has no direct effect on an established thrombus and does not reverse ischemic tissue damage. The goal of anticoagulant therapy is to prevent further extension of an already formed thrombus and to prevent secondary thromboembolic complications that may result in serious and potentially fatal sequelae.</p></div>
<div class="block mst drugH1Div" id="F234925"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Coumadin may be confused with Avandia (DSC), Cardura, Compazine, Kemadrin</p>
<p style="text-indent:-2em;margin-left:4em;">Jantoven may be confused with Janumet, Januvia</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, renal function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Warfarin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients ≥65 years of age (independent of diagnosis or condition) for the initial treatment of venous thromboembolism or nonvalvular atrial fibrillation (unless contraindications or substantial barriers to alternative options) due to high-risk of major bleeding and lower or similar effectiveness compared with direct oral anticoagulants. In older adults already on long-term therapy, continued therapy may be reasonable, especially if INRs are well controlled and there are no adverse effects (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F234911"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F234842"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists. 5-Aminosalicylic Acid Derivatives may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with daily acetaminophen doses exceeding 1.3 or 2 g/day for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease the serum concentration of Vitamin K Antagonists. More specifically, this effect has been described in heavy drinking alcoholic patients (over 250 g alcohol daily for over 3 months).  The role of alcohol itself is unclear.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Monitor for increased prothrombin times (PT)/therapeutic effects of oral anticoagulants if allopurinol is initiated/dose increased, or decreased effects if allopurinol is discontinued/dose decreased. Reductions in coumarin dosage will likely be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. Management: Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is started.  Consider empiric reduction of 30% to 50% in warfarin dose, though no specific guidelines on dose adjustment have been published.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avocado: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May increase the metabolism of Vitamin K Antagonists. Management: Monitor INR more closely. Anticoagulant dose increases of 30% to 60%  may be needed after a barbiturate is initiated or given at an increased dose. Anticoagulant dose decreases may be needed following barbiturate discontinuation or dose reduction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bifonazole: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosentan: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists. Management: Monitor for decreased INR and effects of vitamin K antagonists if carbamazepine is initiated/dose increased, or increased INR and effects if carbamazepine is discontinued/dose decreased. Vitamin K antagonist dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbimazole: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May decrease the serum concentration of Vitamin K Antagonists. Management: Separate the administration of vitamin K antagonists and cholestyramine by at least 3 to 4 hours. Monitor patients closely for reduced vitamin K antagonist effects (eg, decreased INR, thrombosis) when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chondroitin Sulfate: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Avoid coadministration of cimetidine and vitamin K antagonists. If unavoidable, monitor for increased effects of vitamin K antagonists when cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists. Coenzyme Q-10 may enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Vitamin K Antagonists. Management: Monitor for decreased effects of vitamin K antagonists (eg, decreased INR, thrombosis) if combined with moderate CYP2C9 inducers. Vitamin K antagonist dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Weak): May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Weak): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danshen: May enhance the anticoagulant effect of Warfarin. Warfarin may increase the serum concentration of Danshen.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Warfarin. Darunavir may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with other anticoagulants prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Econazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Vitamin K Antagonists. Efavirenz may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: May decrease the serum concentration of Warfarin. Specifically, S-warfarin serum concentrations may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethacrynic Acid: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Ethotoin may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Favipiravir: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenofibrate and Derivatives: May enhance the anticoagulant effect of Warfarin. Fenofibrate and Derivatives may increase the serum concentration of Warfarin. Management: Monitor for signs and symptoms of bleeding, and increase INR monitoring in patients taking warfarin who are initiated on fenofibrate derivatives. Warfarin dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Consider reducing the oral anticoagulant dose by 25% to 33% when initiating a fibric acid derivative. Monitor for toxic or reduced anticoagulant effects if a fibric acid derivative is initiated/dose increased, or discontinued/dose decreased, respectively.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Flucloxacillin may decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives when possible. If combined, consider reducing the vitamin K antagonist dose by 10% to 20% if combined with fluconazole. Monitor for increased anticoagulant effects (ie, increased INR, bleeding) to guide further dose adjustments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May increase the serum concentration of Vitamin K Antagonists. Management: Monitor INR and for signs/symptoms of bleeding closely when a fluorouracil product is combined with a vitamin K antagonist (eg, warfarin). Anticoagulant dose adjustment will likely be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Fosphenytoin-Phenytoin may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Frankincense, Indian: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Vitamin K antagonist dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely for evidence of bleeding and to determine appropriate dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemcitabine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon and Glucagon Analogs: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucosamine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Goji Berry: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: May increase the serum concentration of Vitamin K Antagonists. Hormonal Contraceptives may decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: May enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin. Management: Consider using low-molecular-weight heparin or heparin instead of warfarin. If warfarin and imatinib must be coadministrered, increase monitoring of INR and for signs/symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interferons (Alfa): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Consider alternatives to this combination when possible. If combined, monitor for decreased effectiveness of these CYP2C9 substrates if combined with ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactulose: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May enhance the anticoagulant effect of Warfarin. Leflunomide may diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenvatinib: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevOCARNitine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil and Plant Based): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lornoxicam: May enhance the anticoagulant effect of Vitamin K Antagonists. Lornoxicam may increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macrolide Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Megestrol: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Menadiol Diphosphate: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Menatetrenone: May diminish the anticoagulant effect of Vitamin K Antagonists. Management: Coadministration is not recommended. If concomitant use of menatetrenone and vitamin K antagonists cannot be avoided, monitor coagulation parameters, such as PT/INR.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Menthol: May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: May diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of MetFORMIN.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists. Management: Avoid using any miconazole-containing preparation in patients who are taking warfarin. If coadministration is unavoidable, consider reducing warfarin dose 10% to 20% and monitor for increased warfarin effects (eg, INR, bleeding).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk of bleeding may be increased. MiFEPRIStone may increase the serum concentration of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Management: Consider choosing an alternative antibiotic. Monitor for decreased therapeutic effects and need for dose adjustments of oral anticoagulants if nafcillin is initiated/dose increased, or increased effects if nafcillin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neomycin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Vitamin K Antagonists. Nirmatrelvir and Ritonavir may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Consider alternatives to this combination when possible. If the combination must be used, monitor coagulation status closely and advise patients to promptly report any evidence of bleeding or bruising.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obeticholic Acid: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May enhance the anticoagulant effect of Vitamin K Antagonists. This appears most likely with higher doses (equivalent to acetaminophen doses exceeding 1.3 to 2 g/day) for multiple consecutive days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk of warfarin-induced skin necrosis may be increased. Protein C Concentrate (Human) may diminish the therapeutic effect of Vitamin K Antagonists. This is effect is transient and occurs at the initiation of vitamin K antagonist therapy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: May diminish the anticoagulant effect of Vitamin K Antagonists. Raloxifene may increase the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RaNITIdine (Withdrawn from US Market): May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Remdesivir: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revaprazan: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribavirin (Systemic): May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifamycin Derivatives: May decrease the serum concentration of Vitamin K Antagonists. Management: Consider alternatives if possible. If combined, monitor for reduced anticoagulant effects if a rifamycin derivative is initiated in a vitamin K antagonist treated patient. Vitamin K antagonist dose adjustments will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Avoid as needed use of salicylates in patients taking vitamin K antagonists. Aspirin (80 to 325 mg/day) may be used with warfarin for prevention of cardiovascular events. If coadministering salicylates and vitamin K antagonists, monitor for bledding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates (Topical): May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Zirconium Cyclosilicate: May increase the serum concentration of Warfarin. Management: Separate the administration of sodium zirconium cyclosilicate and warfarin by at least 2 hours. If simultaneous administration is required, monitor for signs and symptoms of warfarin toxicity (eg, elevated INR, bleeding).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Soybean: May diminish the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May decrease the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spinach: May diminish the therapeutic effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May increase the metabolism of Vitamin K Antagonists. Management: Consider avoiding coadministration of St John's Wort and vitamin K antagonists. If combined, monitor for decreased anticoagulant therapeutic effects (eg, decreased INR, thromboembolic events) if St John's Wort is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Streptokinase: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Monitor for decreased vitamin K antagonist effects (eg, decreased INR, thrombosis) when these agents are combined and consider administering vitamin K antagonists at least 2 hours before sucralfate to minimize this interaction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfinpyrazone: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone may decrease the protein binding of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists. Management: Consider reducing the vitamin K antagonist dose by 10% to 20% prior to starting the sulfonamide antibiotic. Monitor INR closely to further guide dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: May increase the serum concentration of Vitamin K Antagonists. Management: Use of a vitamin K antagonist (VKA) is contraindicated when tamoxifen is used to reduce breast cancer incidence and for ductal carcinoma in situ. Monitor VKA closely when tamoxifen is used to treat metastatic breast cancer or as adjuvant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May enhance the anticoagulant effect of Warfarin. Teriflunomide may diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tigecycline: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May increase the serum concentration of Warfarin. Tirzepatide may decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: May enhance the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: May increase the serum concentration of CYP2C9 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranilast (Systemic): May enhance the adverse/toxic effect of Warfarin. Tranilast (Systemic) may diminish the therapeutic effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: May diminish the anticoagulant effect of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zileuton: May increase the serum concentration of Warfarin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F234872"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of oral anticoagulants and increases PT/INR. Chronic daily ethanol use increases the metabolism of oral anticoagulants and decreases PT/INR. Management: Limit alcohol consumption; monitor INR closely.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: The anticoagulant effects of warfarin may be decreased if taken with foods rich in vitamin K. Vitamin E may increase warfarin effect. Cranberry juice may increase warfarin effect. Management: Maintain a consistent diet; consult prescriber before making changes in diet. Take warfarin at the same time each day.</p></div>
<div class="block rep_considerations drugH1Div" id="F53632828"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who may become pregnant. Patients who may become pregnant should use effective contraception during therapy and for 1 month after the last dose.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with mechanical heart valves who are planning a pregnancy may be able to continue therapy depending on the warfarin dose (ACC/AHA [Otto 2021]). Consult current recommendations for appropriate use during pregnancy.</p></div>
<div class="block pri drugH1Div" id="F234859"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Warfarin crosses the placenta; concentrations in the fetal plasma are similar to maternal values.</p>
<p style="text-indent:0em;margin-top:2em;">Teratogenic effects have been reported following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present). Adverse CNS events to the fetus have also been observed following exposure during any trimester and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Spontaneous abortion, fetal hemorrhage, and fetal death may also occur. The teratogenic effects of warfarin may be dose dependent (ACC/AHA [Otto 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Use is contraindicated during pregnancy except in patients with mechanical heart valves who are at high risk for thromboembolism; use is also contraindicated in patients with threatened abortion, eclampsia, or preeclampsia.</p>
<p style="text-indent:0em;margin-top:2em;">Patients with mechanical heart valves have an increased risk of adverse maternal and fetal outcomes and these risks are greater without appropriate anticoagulation. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, venous thromboembolism, hemorrhage), burden of therapy, and maternal preference should be considered. Use of warfarin during the first trimester may be considered if the therapeutic INR can be achieved with a dose ≤5 mg/day. Alternately, adjusted-dose low molecular weight heparin or adjusted-dose heparin may be used until after the first trimester, when therapy can be changed to warfarin, if required. Warfarin should be discontinued and changed to heparin at least 1 week prior to delivery (ACC/AHA [Otto 2021]). Consult current recommendations for appropriate use in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F234860"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Based on available data, warfarin is not present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin is considered compatible with breastfeeding (ACOG 2018). The manufacturer recommends monitoring of breastfeeding infants for bruising or bleeding.</p></div>
<div class="block dic drugH1Div" id="F234861"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Foods high in vitamin K (eg, leafy green vegetables) inhibit anticoagulant effect. The list of usual foods with high vitamin K content is well known, however, some unique ones include green tea (<i>Camellia sinensis</i>), chewing tobacco, a variety of oils (canola, corn, olive, peanut, safflower, sesame seed, soybean, and sunflower) (Booth 1999; Kuykendall 2004; Nutescu 2011). Snack foods containing Olestra have 80 mcg of vitamin K added to each ounce (Harrell 1999). Some natural products may contain hidden sources of vitamin K (Nutescu 2006). Avoid drastic changes in diet (eg, intake of large amounts of alfalfa, asparagus, broccoli, Brussels sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, watercress) which decrease efficacy of warfarin. A balanced diet with a consistent intake of vitamin K is essential. The recommended dietary allowance for vitamin K in adults is 75 to 120 mcg/day (USDA Dietary Reference Intake).</p></div>
<div class="block mop drugH1Div" id="F234847"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Adults:</p>
<p style="text-indent:-2em;margin-left:2em;">Prothrombin time, INR; hematocrit; may consider genotyping of CYP2C9 and VKORC1 prior to initiation of therapy; however, routine genetic testing is not recommended (ACCP [Holbrook 2012]; CPIC [Johnson 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency of INR monitoring: During warfarin initiation, monitor INR daily for hospitalized patients and every 1 to 3 days for nonhospitalized patients. After initiating warfarin therapy, INR should be monitored every 2 to 3 days during the first week of therapy. Once a stable response to therapy is achieved, INR monitoring may be performed less frequently: once a week for the first 1 to 2 weeks, then every 2 weeks, and eventually monthly thereafter. Very stable and reliable patients may have their monitoring extended up to every 12 weeks (Wittkowsky 2018).</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="2" valign="middle">
<p style="text-indent:0em;">Example Frequency of Monitoring by Clinical Setting (Adapted From Wittkowsky 2018)<sup>a</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="2" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup>These example suggestions should not replace clinical judgment; more frequent monitoring may be necessary.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>Initiation of therapy</b></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>Frequency of monitoring</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Inpatient initiation</p></td>
<td align="center">
<p style="text-indent:0em;">Daily.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">After hospital discharge</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">If stable, within 3 to 5 days. If unstable, within 1 to 3 days.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Outpatient flexible initiation</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Daily through day 4, then within 3 to 5 days.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Outpatient average daily dosing method</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Every 3 to 5 days until INR reaches lower limit of therapeutic range, then within 1 week.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">First month of therapy</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">At least weekly.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>Maintenance therapy</b></p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">
<b>Frequency of monitoring</b></p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Medically stable inpatients</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Every 1 to 3 days.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Medically unstable inpatients</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Daily.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">After hospital discharge</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">If stable, within 3 to 5 days. If unstable, within 1 to 3 days.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Routine follow-up in medically stable and reliable patients</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Every 4 to 12 weeks.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Routine follow-up in medically unstable or unreliable patients</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Every 1 to 2 weeks.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Dose held today for significant over-anticoagulation</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Recheck in 1 to 2 days.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Dosage adjustment today</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Recheck within 1 to 2 weeks.</p></td></tr>
<tr>
<td align="center" valign="middle">
<p style="text-indent:0em;">Dosage adjustment ≤2 weeks ago</p></td>
<td align="center" valign="middle">
<p style="text-indent:0em;">Recheck within 2 to 4 weeks.</p></td></tr></tbody></table></div>
<div class="block pha drugH1Div" id="F234836"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Hepatic synthesis of coagulation factors II (half-life 42 to 72 hours), VII (half-life 4 to 6 hours), IX, and X (half-life 27 to 48 hours), as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins’ structure. In the process, “active” vitamin K is oxidatively converted to an “inactive” form, which is then subsequently reactivated by vitamin K epoxide reductase complex 1 (VKORC1). Warfarin competitively inhibits the subunit 1 of the multi-unit VKOR complex, thus depleting functional vitamin K reserves and hence reduces synthesis of active clotting factors. </p></div>
<div class="block phk drugH1Div" id="F234855"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Initial anticoagulant effect on INR may be seen as soon as 24 to 72 hours (Harrison 1997; O’Reilly 1968).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Full therapeutic effect generally seen between 5 and 7 days after initiation; dependent on reduction in vitamin K-dependent coagulation factors, especially prothrombin (factor II), which has a half-life of 60 to 72 hours (ACCP [Ageno 2012]; Crowther 1999; Kovacs 2003; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 2 to 5 days</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 0.14 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP2C9; minor pathways include CYP2C8, 2C18, 2C19, 1A2, and 3A4</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Genomic variants:</i> Approximately 37% reduced clearance of S-warfarin in patients heterozygous for 2C9 (*1/*2 or *1/*3), and ~70% reduced in patients homozygous for reduced function alleles (*2/*2, *2/*3, or *3/*3)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 to 60 hours; Mean: 40 hours; highly variable among individuals</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (92%, primarily as metabolites; minimal as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51192011"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Renal Cl is a minor determinant of anticoagulant response to warfarin.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Hepatic impairment can potentiate the response to warfarin through impaired synthesis of clotting factors and decreased metabolism of warfarin.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Patients 60 years and older appear to exhibit greater than expected INR response to warfarin.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Asian patients may require lower initiation and maintenance doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Pharmacogenetics: Vitamin K epoxide reductase (VKORC1) and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F234862"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Coufatex | Coumadin | Marevan | Warfarin | Warfin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Circuvit | Coumadin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Coumadin sodium | Marevan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ferevan | Unifarin | Warin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Marevan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Marevan | Marfarin | Varfarina sodica | Warfarin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cavamed | Coumadin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Hua fa lin na | Marevan | Orfarin | Panwarfin | Warfarin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Cumarin | Warcok | Warfalife | Warfar | Warfarina | Warfarina sodica</span>;</li>
<li>
<span class="countryCode">(CU)</span> <span class="country">Cuba</span><span class="countrySeparator">: </span><span class="drugName">Warfarina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lawarin | Warfarin | Warfarin Pmcs</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Coumadin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Choice Gador | Coumadin | Coumarex | Plasprin | Warfarina | Warfarina sodica | Warfil</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cicoxil | Coumadin | D.H Warfarina Sod | Warzalin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Warfarin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Caumadin | Haemofarin | Marevan | Marivanil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aldocumar | Tedicumar</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Warfarin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Warfarin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Coumadine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Warfarin | Warfarin sodium almus | Warfarin sodium arrow | Warfarin sodium kent pharm | Warfarin wbp</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Panwarfine | Warfarin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Warfarin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Marivarin | Martefarin | Varfarin PharmaS</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Marfarin | Warfarin orion</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Simarc | Warfarin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Warfant | Warfarin Teva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Coumadin sodium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cofarin | Sofarin | Uni-warfine | Uniwarfin | Warf</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Kovar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Coumadin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Orfarin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Arefarin | Samofaron | Samofaron choseido | Warfarin K | Warfarin potassium towa | Warlin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Warexx</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Couparin | Daehwa warfarin | Jeil wafarin | Kufarin | Panwarfin | Warfa | Warfarin | Warfarin daewha</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Coufatex | Coumadin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aldocumar | Coumadin</span>;</li>
<li>
<span class="countryCode">(LK)</span> <span class="country">Sri Lanka</span><span class="countrySeparator">: </span><span class="drugName">Zofarin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Orfarin | Varfarex | Varfarins | Warfarin | Warfarin SL</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Marevan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Orfarin | Varfarins | Waran | Warfarin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Dimantil | Romesa | Warfarina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Coumadin | Maforan | Marevan | Orfarin | Warfarin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Multichris warfarin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aldocumar | Marevan | Warfarin orion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Marevan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Choice | Coumadin | Warfarina | Warfarina sodica | Warin | Waripharm</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Coumadin sodium | Warik | Xclot | Zyfarin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Anticoag | Blofar | Coagurin | Fericard | Freewarin | Marevan | Warfarin | Warfin | Werifrin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Coumadine | Warfarin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Jantoven | Warfarin Sodium</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Varfarina | Varfine</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Oldin | Rilaquin | Warfarina catedral | Warfarina dasanti | Warfarina icu vita | Warfarina savant pharm | Warfarina sodica empa | Warfarina sodica imedic</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Warfarin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Orfarin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Warfalan | Warfarex | Warfarin | Warfarin canon | Warfarin nycomed | Warfarin obl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Coufatex | Coumadin | Marevan | Warfarin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Waran | Warfarin nycomed | Warfarin orion</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo warfarin | Coumadin | Marevan | Orfarin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Marevan | Marivarin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lawarin | Orfarin | Warfarin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Befarin | Coumadin | Farin | Maforan | Morfarin | Orfarin | Tufam | Warfarin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Coumadin | Orfarin | Warfmadin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Athrombin-K | Cofarin | Coumadin | Mafarin | Marevan | Uwarin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Warfarex | Warfarin | Warfarin fs</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Choice | Coumadin | Dagonal | Warfarina | Warfarina Icu</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anasmol | Coumadin | Cumar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen warfarin | Cipla warfarin | Gesavin | Segavin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Warf | Warfarin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lennon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33391959">
<a name="33391959"></a>Abutaki FH, Alfaraj D, Alshahrani A, Elsharkawy T. Warfarin-induced calciphylaxis in a COVID-19 patient. <i>Cureus</i>. 2020;12(12):e12249. doi:10.7759/cureus.12249<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/33391959/pubmed" id="33391959" target="_blank">33391959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315269">
<a name="22315269"></a>Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e44S-e88S. doi: 10.1378/chest.11-2292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315269/pubmed" id="22315269" target="_blank">22315269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26783010">
<a name="26783010"></a>Al-ani M, Parperis K. Warfarin-induced calciphylaxis. <i>BMJ Case Rep</i>. 2016;2016:bcr2015214142. doi:10.1136/bcr-2015-214142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26783010/pubmed" id="26783010" target="_blank">26783010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists' (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23713086">
<a name="23713086"></a>Armstrong MJ, Gronseth G, Anderson DC, et al. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2013;80(22):2065-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23713086/pubmed" id="23713086" target="_blank">23713086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi: 10.1111/j.1538-7836.2012.04662.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22269622">
<a name="22269622"></a>Baillargeon J, Holmes HM, Lin YL, et al, "Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults," <i>Am J Med</i>, 2012, 125(2):183-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22269622/pubmed" id="22269622" target="_blank">22269622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15695604">
<a name="15695604"></a>Barnes C, Newall F, Ignjatovic V, Wong P, Cameron F, Jones G, Monagle P. Reduced bone density in children on long-term warfarin. <i>Pediatr Res</i>. 2005;57(4):578-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/15695604/pubmed" id="15695604" target="_blank">15695604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315276">
<a name="22315276"></a>Bates SM, Greer IA, Middeldorp S, et al. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest.</i> 2012;141(2)(suppl):e691-e736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315276/pubmed" id="22315276" target="_blank">22315276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23645479">
<a name="23645479"></a>Bechtel P, Boorse R, Rovito P, Harrison TD, Hong J. Warfarin users prone to coagulopathy in first 30 days after hospital discharge from gastric bypass. <i>Obes Surg</i>. 2013;23(10):1515-1519. doi: 10.1007/s11695-013-0972-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23645479/pubmed" id="23645479" target="_blank">23645479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25511666">
<a name="25511666"></a>Bendaly EA, DiMeglio LA, Fadel WF, Hurwitz RA. Bone density in children with single ventricle physiology. <i>Pediatr Cardiol</i>. 2015;36(4):779-785. doi: 10.1007/s00246-014-1083-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25511666/pubmed" id="25511666" target="_blank">25511666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10568341">
<a name="10568341"></a>Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. <i>Nutr Rev</i>.1999;57(9):288-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10568341/pubmed" id="10568341" target="_blank">10568341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23891426">
<a name="23891426"></a>Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. <i>Am J Cardiol</i>. 2013;112(9):1439-1444. doi:10.1016/j.amjcard.2013.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23891426/pubmed" id="23891426" target="_blank">23891426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24925541">
<a name="24925541"></a>Cakebread HE, Knight HM, Gajendragadkar PR, Cooper JP. Warfarin-induced purple toe syndrome successfully treated with apixaban. <i>BMJ Case Rep</i>. 2014;2014:bcr2014205320. doi:10.1136/bcr-2014-205320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24925541/pubmed" id="24925541" target="_blank">24925541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28330690">
<a name="28330690"></a>Chakravarty T, Søndergaard L, Friedman J, et al; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. <i>Lancet</i>. 2017;389(10087):2383-2392. doi:10.1016/S0140-6736(17)30757-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28330690/pubmed" id="28330690" target="_blank">28330690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Coumadin.1">
<a name="Coumadin.1"></a>Coumadin (warfarin) [prescribing information]. Princeton, NJ: Bristol-Meyers Squibb Company; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9892329">
<a name="9892329"></a>Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. <i>Arch Intern Med</i>. 1999;159(1):46-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9892329/pubmed" id="9892329" target="_blank">9892329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv</i>. 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8355108">
<a name="8355108"></a>David M, Andrew M. Venous Thromboembolic Complications in Children. <i>J Pediatr</i>. 1993;123(3):337-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/8355108/pubmed" id="8355108" target="_blank">8355108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9619702">
<a name="9619702"></a>Del Sette M, Angeli S, Gandolfo C. Warfarin, aspirin and microembolic signals in the acute phase of stroke in a patient with mechanical heart valves. <i>Cerebrovasc Dis</i>. 1998;8(3):182-183. doi:10.1159/000015844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9619702/pubmed" id="9619702" target="_blank">9619702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26381781">
<a name="26381781"></a>Demir S, Ozdag MF, Kendirli MT, Togrol RE. What do anticoagulants say about microemboli? <i>J Stroke Cerebrovasc Dis</i>. 2015;24(11):2474-2477. doi:10.1016/j.jstrokecerebrovasdis.2015.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26381781/pubmed" id="26381781" target="_blank">26381781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24584210">
<a name="24584210"></a>Eckersley L, Stirling J, Occleshaw C, Wilson N. Two cases of warfarin-induced tracheobronchial calcification after Fontan surgery. <i>Pediatr Cardiol</i>. 2014;35(6):954-958. doi:10.1007/s00246-014-0880-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24584210/pubmed" id="24584210" target="_blank">24584210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720522">
<a name="17720522"></a>Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. <i>Am J Kidney Dis</i>. 2007;50(3):433-440. doi:10.1053/j.ajkd.2007.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/17720522/pubmed" id="17720522" target="_blank">17720522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Erkan.1">
<a name="Erkan.1"></a>Erkan D, Ortel TL. Treatment of antiphospholipid syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e278S-e325S. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12875753">
<a name="12875753"></a>Fukumoto Y, Tsutsui H, Tsuchihashi M, Masumoto A, Takeshita A; Cholesterol Embolism Study(CHEST) Investigators. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. <i>J Am Coll Cardiol</i>. 2003;42(2):211-216. doi:10.1016/s0735-1097(03)00579-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12875753/pubmed" id="12875753" target="_blank">12875753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24226806">
<a name="24226806"></a>Giglia TM, Massicotte MP, Tweddell JS, et al.; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703. doi:10.1161/01.cir.0000436140.77832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24226806/pubmed" id="24226806" target="_blank">24226806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23615629">
<a name="23615629"></a>Golding LP, Walsh MJ, Sumner TE, Nakagawa TA. Tracheobronchial calcifications in children. <i>Pediatr Radiol</i>. 2013;43(8):937-940. doi:10.1007/s00247-013-2649-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23615629/pubmed" id="23615629" target="_blank">23615629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23184840">
<a name="23184840"></a>Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Hellings C, Juurlink DN. Rates of hemorrhage during warfarin therapy for atrial fibrillation. <i>CMAJ</i>. 2013;185(2):E121-E127. doi:10.1503/cmaj.121218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23184840/pubmed" id="23184840" target="_blank">23184840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hadlock.1">
<a name="Hadlock.1"></a>Hadlock GC, Burnett AE, Nutescu EA. Warfarin. In: Lau JF, Barnes GD, Streiff MB, eds. <i>Anticoagulation Therapy.</i> New York, NY: Springer Publishing; 2018:9-30.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23581997">
<a name="23581997"></a>Hafiji J, Deegan P, Brais R, Norris P. Warfarin-induced calciphylaxis successfully treated with sodium thiosulphate. <i>Australas J Dermatol</i>. 2013;54(2):133-135. doi:10.1111/j.1440-0960.2011.00861.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23581997/pubmed" id="23581997" target="_blank">23581997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509671">
<a name="15509671"></a>Hanley JP. Warfarin reversal. <i>J Clin Pathol</i>. 2004;57(11):1132-1139. doi:10.1136/jcp.2003.008904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/15509671/pubmed" id="15509671" target="_blank">15509671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34872740">
<a name="34872740"></a>Hardin J, Michelson AD, McCrindle BW, et al. Real-world anticoagulant use and incidence of venous thromboembolism and major bleeding in children. <i>Clin Ther</i>. 2021;43(12):2074-2087. doi:10.1016/j.clinthera.2021.09.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/34872740/pubmed" id="34872740" target="_blank">34872740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10501114">
<a name="10501114"></a>Harrell CC, Kline SS. Vitamin K-supplemented snacks containing olestra: implication for patients taking warfarin. <i>JAMA</i>. 1999;282(12):1133-1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10501114/pubmed" id="10501114" target="_blank">10501114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9005747">
<a name="9005747"></a>Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. <i>Ann Intern Med</i>. 1997;126(2):133-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/9005747/pubmed" id="9005747" target="_blank">9005747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28552474">
<a name="28552474"></a>Hepponstall M, Chan A, Monagle P. Anticoagulation therapy in neonates, children and adolescents. <i>Blood Cells Mol Dis</i>. 2017;67:41-47. doi:10.1016/j.bcmd.2017.05.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28552474/pubmed" id="28552474" target="_blank">28552474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315259">
<a name="22315259"></a>Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e152S-e184S. doi:10.1378/chest.11-2295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315259/pubmed" id="22315259" target="_blank">22315259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.1">
<a name="Hull.1"></a>Hull RD, Garcia DA, Burnett AE. Heparin and LMW heparin: dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.2">
<a name="Hull.2"></a>Hull RD, Lip G. Venous thromboembolism: anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 12, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3605140">
<a name="3605140"></a>Hyman BT, Landas SK, Ashman RF, Schelper RL, Robinson RA. Warfarin-related purple toes syndrome and cholesterol microembolization. <i>Am J Med</i>. 1987;82(6):1233-1237. doi:10.1016/0002-9343(87)90231-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/3605140/pubmed" id="3605140" target="_blank">3605140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28469497">
<a name="28469497"></a>Igarashi Y, Akimoto T, Kobayashi T, et al. Performing anticoagulation: A puzzling case of cholesterol embolization syndrome. <i>Clin Med Insights Case Rep</i>. 2017;10:1179547616684649. doi:10.1177/1179547616684649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28469497/pubmed" id="28469497" target="_blank">28469497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jantoven.1">
<a name="Jantoven.1"></a>Jantoven (warfarin) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories Inc; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. <i>Circulation</i>. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28198005">
<a name="28198005"></a>Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. <i>Clin Pharmacol Ther</i>. 2017;102(3):397-404. doi:10.1002/cpt.668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28198005/pubmed" id="28198005" target="_blank">28198005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28385406">
<a name="28385406"></a>Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. <i>JACC Cardiovasc Interv</i>. 2017;10(7):686-697. doi:10.1016/j.jcin.2017.01.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28385406/pubmed" id="28385406" target="_blank">28385406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24648693">
<a name="24648693"></a>Kakagia DD, Papanas N, Karadimas E, Polychronidis A. Warfarin-induced skin necrosis. <i>Ann Dermatol</i>. 2014;26(1):96-98. doi:10.5021/ad.2014.26.1.96<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24648693/pubmed" id="24648693" target="_blank">24648693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30839325">
<a name="30839325"></a>Kansara T, Tornay J, Agarwal S. Warfarin-associated tracheobronchial calcification. <i>Am J Ther</i>. 2019;26(6):e787-e788. doi:10.1097/MJT.0000000000000961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30839325/pubmed" id="30839325" target="_blank">30839325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21764203">
<a name="21764203"></a>Karsli ED, Erdogan Ö, Esen E, et al. Comparison of the Effects of Warfarin and Heparin on Bleeding Caused by Dental Extraction: A Clinical Study. <i>J Oral Maxillofac Surg</i>. 2011;69(10):2500-2507.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21764203/pubmed" id="21764203" target="_blank">21764203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi:10.1378/chest.11-2301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30354550">
<a name="30354550"></a>Khan MS, Usman MS, Siddiqi TJ, et al. Is anticoagulation beneficial in pulmonary arterial hypertension? <i>Circ Cardiovasc Qual Outcomes</i>. 2018;11(9):e004757. doi:10.1161/CIRCOUTCOMES.118.004757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30354550/pubmed" id="30354550" target="_blank">30354550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25197328">
<a name="25197328"></a>Kim H, Zhen DB, Lieske JC, et al. Treatment of cholesterol embolization syndrome in the setting of an acute indication for anticoagulation therapy. <i>J Med Cases</i>. 2014;5(6):376-379. doi:10.14740/jmc1804w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25197328/pubmed" id="25197328" target="_blank">25197328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Konkle.1">
<a name="Konkle.1"></a>Konkle BA, Nkomo VT. Antithrombotic therapy for mechanical heart valves. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12729425">
<a name="12729425"></a>Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together With Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. A Randomized, Double-Blind, Controlled Trial. <i>Ann Intern Med</i>. 2003;138(9):714-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/12729425/pubmed" id="12729425" target="_blank">12729425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569516">
<a name="23569516"></a>Kumar M, Abrina VM, Chittimireddy S. Coumadin-induced skin necrosis in a 64 year-old female despite LMWH bridging therapy. <i>Am J Case Rep</i>. 2012;13:157-159. doi:10.12659/AJCR.883247<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23569516/pubmed" id="23569516" target="_blank">23569516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J<i> Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16369639">
<a name="16369639"></a>Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. <i>Proc (Bayl Univ Med Cent)</i>. 2001;14(3):305-306. doi:10.1080/08998280.2001.11927781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16369639/pubmed" id="16369639" target="_blank">16369639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14766993">
<a name="14766993"></a>Kuykendall JR, Houle MD, Rhodes RS. Possible warfarin failure due to interaction with smokeless tobacco. <i>Ann Pharmacother</i>. 2004;38(4):595-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/14766993/pubmed" id="14766993" target="_blank">14766993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25873727">
<a name="25873727"></a>Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. <i>Circ Cardiovasc Interv</i>. 2015;8(4):e001779. doi:10.1161/CIRCINTERVENTIONS.114.001779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25873727/pubmed" id="25873727" target="_blank">25873727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leung.1">
<a name="Leung.1"></a>Leung L. Direct oral anticoagulants and parenteral direct thrombin inhibitors: dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36106537">
<a name="36106537"></a>Levine GN, McEvoy JW, Fang JC, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(15):e205-e223. doi:10.1161/CIR.0000000000001092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/36106537/pubmed" id="36106537" target="_blank">36106537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19225037">
<a name="19225037"></a>Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. <i>J Am Soc Nephrol</i>. 2009;20(4):912-921. doi:10.1681/ASN.2008070802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/19225037/pubmed" id="19225037" target="_blank">19225037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20709439">
<a name="20709439"></a>Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. <i>Am J Kidney Dis</i>. 2010;56(5):823-831. doi:10.1053/j.ajkd.2010.05.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/20709439/pubmed" id="20709439" target="_blank">20709439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2015;148(6):1529]. <i>Chest</i>. 2012;141(2)(suppl):e495S-e530S. doi:10.1378/chest.11-2303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22187399">
<a name="22187399"></a>Macartney CA, Chan AK. Thrombosis in children. <i>Semin Thromb Hemost</i>. 2011;37(7):763-761. doi:10.1055/s-0031-1297167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22187399/pubmed" id="22187399" target="_blank">22187399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26436963">
<a name="26436963"></a>Makkar RR, Fontana G, Jilaihawi H, et al Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. <i>N Engl J Med</i>. 2015;373(21):2015-2024. doi:10.1056/NEJMoa1509233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26436963/pubmed" id="26436963" target="_blank">26436963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332472">
<a name="19332472"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association [published correction appears in <i>Circulation. </i>2009;120(2):e13]. <i>Circulation</i>. 2009;119(16):2250-2294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/19332472/pubmed" id="19332472" target="_blank">19332472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32528755">
<a name="32528755"></a>Medepalli VM, Davis LS, Medepalli LC, Padala SA. Calciphylaxis in the setting of hemodialysis, liver cirrhosis, and warfarin therapy for atrial fibrillation: An argument for alternative anti-embolic therapy. <i>Cureus</i>. 2020;12(5):e8014. doi:10.7759/cureus.8014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/32528755/pubmed" id="32528755" target="_blank">32528755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315277">
<a name="22315277"></a>Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, Vesely SK. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2)(suppl):e737S-e801S. doi:10.1378/chest.11-2308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315277/pubmed" id="22315277" target="_blank">22315277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31439554">
<a name="31439554"></a>Munawar T, Ibe U, Jiwa N, Raissi S. Renal cholesterol crystal embolism in the setting of warfarin use. <i>BMJ Case Rep</i>. 2019;12(8):e230314. doi:10.1136/bcr-2019-230314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/31439554/pubmed" id="31439554" target="_blank">31439554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19615543">
<a name="19615543"></a>Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. <i>J Am Acad Dermatol</i>. 2009;61(2):325-332. doi:10.1016/j.jaad.2008.12.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/19615543/pubmed" id="19615543" target="_blank">19615543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14595081">
<a name="14595081"></a>Newall F, Barnes C, Savoia H, Campbell J, Monagle P. Warfarin therapy in children who require long-term total parenteral nutrition. <i>Pediatrics</i>. 2003;112(5):e386.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/14595081/pubmed" id="14595081" target="_blank">14595081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15574639">
<a name="15574639"></a>Newburger JW, Takahashi M, Gerber MA, et al.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. <i>Pediatrics</i>. 2004;114(6):1708-1733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/15574639/pubmed" id="15574639" target="_blank">15574639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21359645">
<a name="21359645"></a>Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. <i>J Thromb Thrombolysis</i>. 2011;31:326-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/21359645/pubmed" id="21359645" target="_blank">21359645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16610971">
<a name="16610971"></a>Nutescu E, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. <i>Expert Opin Drug Saf</i>. 2006;5(3):433-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/16610971/pubmed" id="16610971" target="_blank">16610971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23585642">
<a name="23585642"></a>Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. <i>Ann Pharmacother</i>. 2013;47(5):714-724. doi:10.1345/aph.1R634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23585642/pubmed" id="23585642" target="_blank">23585642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11712286">
<a name="11712286"></a>O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. <i>Circulation</i>. 1968;38(1):169-177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/11712286/pubmed" id="11712286" target="_blank">11712286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24081973">
<a name="24081973"></a>Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). <i>Circulation</i>. 2014;129(1):57-65. doi:10.1161/CIRCULATIONAHA.113.004526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24081973/pubmed" id="24081973" target="_blank">24081973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30701002">
<a name="30701002"></a>Ozturk M, Ipekci A, Kiyak SK, et al. Bleeding complications in warfarin-treated patients admitted to the emergency department. <i>J Clin Med Res</i>. 2019;11(2):106-113. doi:10.14740/jocmr3669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/30701002/pubmed" id="30701002" target="_blank">30701002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pasupala.2012">
<a name="Pasupala.2012"></a>Pasupala U, Soare M, Dianne S, et al. Atheroembolic renal disease and anticoagulants use: A case report and literature review. <i>World Journal of Nephrology &amp; Urology</i>. 2012;1(4-5):115-117.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pislaru.1">
<a name="Pislaru.1"></a>Pislaru S, Connolly HM. Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24829402">
<a name="24829402"></a>Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. <i>Eur J Cardiothorac Surg</i>. 2015;47(4):725-732. doi:10.1093/ejcts/ezu201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24829402/pubmed" id="24829402" target="_blank">24829402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24512654">
<a name="24512654"></a>Puskas J, Gerdisch M, Nichols D, et al; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration Investigational Device Exemption Trial. <i>J Thorac Cardiovasc Surg</i>. 2014;147(4):1202-1211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24512654/pubmed" id="24512654" target="_blank">24512654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32222786">
<a name="32222786"></a>Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. <i>Eur J Clin Pharmacol</i>. 2020;76(6):867-876. doi:10.1007/s00228-020-02856-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/32222786/pubmed" id="32222786" target="_blank">32222786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23966800">
<a name="23966800"></a>Saifan C, Saad M, El-Charabaty E, El-Sayegh S. Warfarin-induced calciphylaxis: a case report and review of literature. <i>Int J Gen Med</i>. 2013;6:665-669. doi:10.2147/IJGM.S47397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/23966800/pubmed" id="23966800" target="_blank">23966800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24851819">
<a name="24851819"></a>Sakaan SA, Hudson JQ, Oliphant CS, et al. Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease. <i>Pharmacotherapy</i>. 2014;34(7):695-702. doi:10.1002/phar.1445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/24851819/pubmed" id="24851819" target="_blank">24851819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25826733">
<a name="25826733"></a>Schullo-Feulner AM, Stoecker Z, Brown GA, Schneider J, Jones TA, Burnett B. Warfarin dosing after bariatric surgery: a retrospective study of 10 patients previously stable on chronic warfarin therapy. <i>Clin Obes</i>. 2014;4(2):108-115. doi:10.1111/cob.12046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/25826733/pubmed" id="25826733" target="_blank">25826733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31652944">
<a name="31652944"></a>Signorelli SS, Scuto S, Marino E, Giusti M, Xourafa A, Gaudio A. Anticoagulants and osteoporosis. <i>Int J Mol Sci</i>. 2019;20(21):5275. doi:10.3390/ijms20215275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/31652944/pubmed" id="31652944" target="_blank">31652944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26406775">
<a name="26406775"></a>Steffen KJ, Wonderlich JA, Erickson AL, Strawsell H, Mitchell JE, Crosby RD. Comparison of warfarin dosages and international normalized ratios before and after Roux-en-Y gastric bypass surgery. <i>Pharmacotherapy</i>. 2015;35(9):876-880. doi:10.1002/phar.1632<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/26406775/pubmed" id="26406775" target="_blank">26406775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10556183">
<a name="10556183"></a>Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, Mitchell L. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. <i>Blood.</i> 1999;94(9):3007-3014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/10556183/pubmed" id="10556183" target="_blank">10556183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29496441">
<a name="29496441"></a>Strong AT, Sharma G, Nor Hanipah Z, et al. Adjustments to warfarin dosing after gastric bypass and sleeve gastrectomy. <i>Surg Obes Relat Dis</i>. 2018;14(5):700-706. doi:10.1016/j.soard.2017.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/29496441/pubmed" id="29496441" target="_blank">29496441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USDA.1">
<a name="USDA.1"></a>United States Department of Agriculture (USDA), National Agricultural Library (NAL) <i>Dietary Reference Intake</i>. <a href="http://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-tables" target="_blank">http://fnic.nal.usda.gov/dietary-guidance/dietary-reference-intakes/dri-tables</a>. Accessed January 8, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315274">
<a name="22315274"></a>Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest. </i>2012;141(4):1129]. <i>Chest</i>. 2012;141(2)(suppl):e637S-e668S. doi:10.1378/chest.11-2306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/22315274/pubmed" id="22315274" target="_blank">22315274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20308269">
<a name="20308269"></a>Varis J, Kuusniemi K, Järveläinen H. Cholesterol microembolization syndrome: a complication of anticoagulant therapy. <i>CMAJ</i>. 2010;182(9):931-933. doi:10.1503/cmaj.090919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/20308269/pubmed" id="20308269" target="_blank">20308269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Warfarin [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; November 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27747798">
<a name="27747798"></a>Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature. <i>Drugs Real World Outcomes</i>. 2016;3(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/27747798/pubmed" id="27747798" target="_blank">27747798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wittkowsky.1">
<a name="Wittkowsky.1"></a>Wittkowsky AK. Warfarin. In: Dager WE, Gulseth MP, Nutescu EA, eds. <i>Anticoagulation Therapy: A Clinical Practice Guide.</i> 2nd ed. American Society of Health-System Pharmacists; 2018:13-34.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17620536">
<a name="17620536"></a>Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. <i>Arch Intern Med</i>. 2007;167(13):1414-1419. doi:10.1001/archinte.167.13.1414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/17620536/pubmed" id="17620536" target="_blank">17620536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099971">
<a name="28099971"></a>Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. <i>JAMA Dermatol</i>. 2017;153(3):309-314. doi:10.1001/jamadermatol.2016.4821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/warfarin-drug-information/abstract-text/28099971/pubmed" id="28099971" target="_blank">28099971</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10050 Version 610.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
